Summary & Overview
HCPCS J9198: Gemcitabine Hydrochloride Injection, 100 mg
HCPCS Level II code J9198 denotes a 100 mg unit of gemcitabine hydrochloride (Infugem) administered as an antineoplastic injection. As a unit-based drug code, J9198 is central to billing chemotherapy infusions and impacts facility and professional service lines nationwide. Accurate use ensures proper capture of drug utilization and supports payment for outpatient cancer treatment.
Key payers evaluated include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for gemcitabine use, typical sites of service for billing, and the operational implications for infusion centers and oncology practices.
This publication provides benchmarks on code usage and reimbursement where available, summarizes relevant billing considerations for outpatient infusion services, and highlights common modifiers and service-line interactions that affect claims processing. Data not available in the input are noted explicitly. The content is intended for national audiences including billing staff, revenue cycle managers, and oncology practice administrators seeking a clear, practical reference for HCPCS Level II code J9198.
Billing Code Overview
HCPCS Level II code J9198 represents an injection of gemcitabine hydrochloride (Infugem), 100 mg supplied for intravenous administration. This billing code is used to report the drug product by unit strength and typically reflects administration as part of chemotherapy regimens.
Service Type: Chemotherapy drug administration (intravenous antineoplastic agent)
Typical Site of Service: Hospital outpatient infusion center, physician office infusion suite, or ambulatory infusion center
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a solid tumor diagnosis (for example, metastatic pancreatic, non-small cell lung, or bladder cancer) receiving outpatient intravenous chemotherapy with gemcitabine (J9198, per 100 mg). The patient arrives to the oncology infusion center or hospital outpatient infusion suite for a scheduled cycle. Clinical workflow: triage and vital signs, review of laboratory results (complete blood count, renal and hepatic panels) to confirm adequate counts and organ function, verification of the chemotherapy order and dose calculation (weight- or body-surface-area–based), preparation of gemcitabine by pharmacy under sterile compounding procedures, administration via intravenous infusion (often over 30 minutes to 2 hours depending on regimen), monitoring during and after infusion for infusion reactions and hematologic toxicities, documentation of lot numbers and units administered, and billing using J9198 with appropriate modifier(s) to reflect circumstances of the service.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered to any patient | Use when a portion of the single-use vial of gemcitabine is discarded and must be reported per payer policy for wasted drug billing. |